EKSO Valuation

Ekso Bionics Holdings Inc

Add to Watchlist

Advanced Chart

3.750

-0.14(-3.599%)1D

Overview
Forecast
Valuation
Earnings

EKSO Relative Valuation

EKSO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EKSO is overvalued; if below, it's undervalued.

Historical Valuation

Ekso Bionics Holdings Inc (EKSO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.54 is considered Fairly compared with the five-year average of -3.14. The fair price of Ekso Bionics Holdings Inc (EKSO) is between 2.50 to 26.54 according to relative valuation methord.

Relative Value

Fair Zone

2.50-26.54

Current Price：3.75

Fair

-1.93

Trailing

Forward

0.00

EV/EBITDA

Ekso Bionics Holdings Inc. (EKSO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.54. The thresholds are as follows: Strongly Undervalued below -5.34, Undervalued between -5.34 and -2.94, Fairly Valued between 1.86 and -2.94, Overvalued between 1.86 and 4.27, and Strongly Overvalued above 4.27. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.24

EV/EBIT

Ekso Bionics Holdings Inc. (EKSO) has a current EV/EBIT of -1.24. The 5-year average EV/EBIT is -1.49. The thresholds are as follows: Strongly Undervalued below -5.24, Undervalued between -5.24 and -3.37, Fairly Valued between 0.39 and -3.37, Overvalued between 0.39 and 2.27, and Strongly Overvalued above 2.27. The current Forward EV/EBIT of -1.24 falls within the Historic Trend Line -Fairly Valued range.

0.53

Ekso Bionics Holdings Inc. (EKSO) has a current PS of 0.53. The 5-year average PS is 2.20. The thresholds are as follows: Strongly Undervalued below -2.16, Undervalued between -2.16 and 0.02, Fairly Valued between 4.38 and 0.02, Overvalued between 4.38 and 6.56, and Strongly Overvalued above 6.56. The current Forward PS of 0.53 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Ekso Bionics Holdings Inc. (EKSO) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.24. The thresholds are as follows: Strongly Undervalued below -3.02, Undervalued between -3.02 and -1.63, Fairly Valued between 1.15 and -1.63, Overvalued between 1.15 and 2.54, and Strongly Overvalued above 2.54. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Ekso Bionics Holdings Inc. (EKSO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.20. The thresholds are as follows: Strongly Undervalued below -2.99, Undervalued between -2.99 and -1.59, Fairly Valued between 1.20 and -1.59, Overvalued between 1.20 and 2.59, and Strongly Overvalued above 2.59. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Ekso Bionics Holdings Inc (EKSO) has a current Price-to-Book (P/B) ratio of 0.89. Compared to its 3-year average P/B ratio of 1.14 , the current P/B ratio is approximately -21.34% higher. Relative to its 5-year average P/B ratio of -20.27, the current P/B ratio is about -104.41% higher. Ekso Bionics Holdings Inc (EKSO) has a Forward Free Cash Flow (FCF) yield of approximately -90.53%. Compared to its 3-year average FCF yield of -74.02%, the current FCF yield is approximately 22.30% lower. Relative to its 5-year average FCF yield of -54.92% , the current FCF yield is about 64.85% lower.

0.93

P/B

Median3y

1.14

Median5y

-20.27

-92.68

FCF Yield

Median3y

-74.02

Median5y

-54.92

Competitors Valuation Multiple

The average P/S ratio for EKSO's competitors is 1.51, providing a benchmark for relative valuation. Ekso Bionics Holdings Inc Corp (EKSO) exhibits a P/S ratio of 0.53, which is -64.79% above the industry average. Given its robust revenue growth of -58.44%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

EKSO.O

Ekso Bionics Holdings Inc

SINTX Technologies Inc

Predictive Oncology Inc

0.92

-96.01%

9.97M

Performance Decomposition

Market capitalization of EKSO decreased by 79.17% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -48.81 to -131.70.

The secondary factor is the Revenue Growth, contributed -58.44%to the performance.

Overall, the performance of EKSO in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-58.44%

4.95M → 2.06M

Revenue Growth

169.82%

-48.81 → -131.70

Margin Expansion

-190.55%

0.63 → -0.57

P/E Change

-79.17%